Clinical Trials Directory

Trials / Completed

CompletedNCT00792753

Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"

A Randomized, Single Blind, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions And A Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
360 (actual)
Sponsor
Elixir Medical Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of clinical, angiographic and IVUS endpoints as compared to the concurrently enrolled Medtronic Zotarolimus-Eluting Coronary Stent System in a randomized, single blind study of up to 200 male and female patients. In a Continued Access Registry of up to 100 patients receiving the DESyne Stent clinical-only endpoints will be evaluated. To evaluate the safety and effectiveness of the Elixir Novolimus-Eluting Coronary Stent System with bioabsorbable polymer as compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System control through clinical and angiographic endpoints.

Conditions

Interventions

TypeNameDescription
DEVICEMedtronic Endeavor Coronary Stent Systemcoronary stent implantation
DEVICEDESyne BD Novolimus Stent Systemcoronary stent implantation
DEVICEDESyne Novolimus Stent Systemcoronary stent implantation

Timeline

Start date
2008-10-01
Primary completion
2011-11-01
Completion
2014-03-08
First posted
2008-11-18
Last updated
2020-04-08

Locations

8 sites across 8 countries: Australia, Belgium, Brazil, Germany, Netherlands, New Zealand, Poland, Switzerland

Source: ClinicalTrials.gov record NCT00792753. Inclusion in this directory is not an endorsement.